m****g 发帖数: 530 | 1 Data Suggest Pfizer's Humanized Anti-Amyloid Monoclonal Antibody was Well-
Tolerated in Patients with
Mild to Moderate Alzheimer's Disease
Safety Results from Dimebon in Combination with Donepezil Showed that
Combination was Well-Tolerated
NEW YORK--(BUSINESS WIRE)--Jul 15, 2009 - Pfizer Inc announced today results
from two Phase 1 safety
studies, one of PF-04360365, a humanized anti-amyloid monoclonal antibody (
mAb), and another of
dimebon (latrepirdine*) in combination with donepezil HCl tabl |
|